Cullinan Therapeutics Inc (CGEM)
$19.15
+0.26
(+1.38%)▲
Live
Insights on Cullinan Therapeutics Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 280.7%
Performance
- $18.23$19.43$19.15
4.8%
Downside
Day's Volatility :6.18%
Upside
1.44%
- $7.64$20.62$19.15
60.1%
Downside
52 Weeks Volatility :62.95%
Upside
7.13%
Returns
| Period | Cullinan Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 45.31% | 1.7% | 0.0% |
6 Months | 121.71% | 11.3% | 0.0% |
1 Year | 81.11% | 5.4% | 1.3% |
3 Years | -40.37% | 13.9% | -22.1% |
Highlights
Market Capitalization | 813.5M |
Book Value | $10.58 |
Earnings Per Share (EPS) | -3.69 |
Wall Street Target Price | 28.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -22.8% |
Return On Equity TTM | -31.37% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 18.9M |
EBITDA | -190.3M |
Diluted Eps TTM | -3.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.34 |
EPS Estimate Next Year | -3.09 |
EPS Estimate Current Quarter | -0.96 |
EPS Estimate Next Quarter | -0.96 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 46.21%
Technicals Summary
Sell
Neutral
Buy
Cullinan Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cullinan Therapeutics Inc | 11.58% | 121.71% | 81.11% | -40.37% | 47125.0% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cullinan Therapeutics Inc | 9.03 | NA | NA | -3.34 | -0.31 | -0.23 | NA | 10.58 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cullinan Therapeutics Inc | Buy | $813.5M | 47125.0% | 9.03 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
MPM Oncology Impact Management LP
17.76%Blue Owl Capital Holdings LP
7.94%CHI Advisors LLC
7.93%Franklin Resources Inc
7.62%Bvf Inc
7.42%BlackRock Inc
5.72%
Company Information
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Organization | Cullinan Therapeutics Inc |
Employees | 85 |
CEO | Mr. Nadim Ahmed |
Industry | Other Consumer Services |
